NR566_Week_2_Instructor_Questions

• There iare iseveral itreatment ioptions ifor iCAP. iSpecific icriteria iare iused ito idetermine ithe iappropriate itreatment ifor ieach ipatient, iincluding ipresence iof icomorbidities iand iprevious iantibiotic iuse. iIf ithe ipatient iused iantibiotics iwithin ithe iprevious i3 imonths, ithen icoverage is iextended. iThere iare itwo itools ithat iare ialso iused ito idetermine iif ithe ipatient ishould ibe itreated ias ioutpatient ior iinpatient. iThese iare ithe iPSI iand iCURB-65 itools. iAntibiotic itreatments iwill ivary iby isetting. iYou ilisted i2 imain iantibiotic iclasses ithat iare iused. iAn iimportant iside-effect ito ibe iaware iof iwith imacrolides iis ithe irisk iof iQT iprolongation. • What iare isome iother iimportant idifference ibetween ithe imacrolides ithat iwould imake iyou ichoose ione iagent iover ianother? o Azithromycin idoes ihave ithe ibest isafety iprofile iamong ithe imacrolides. iIt iis ialso ieasier ito icomply iwith isince iit iis idosed ionce idaily, iwhile iclarithromycin iis idosed itwice idaily iand ierythromycin ifour itimes idaily. iThese iother itwo imacrolides ialso ihave imany iserious idrug iinteractions. iErythromycin ihas ia ilot iof iGI iside-effects ithat ican ibe idifficult ito itolerate. iThis iis iwhy iyou iwill isee iazithromycin iused ialmost iexclusively iin ipractice. iYou imay isee ithe iother imacrolides iused ifor imore iunique iindications. • Peripheral ineuropathy iis ia itroublesome iside-effect iof iisoniazid. iWhat iare isome iof ithe isymptoms iof iPN, iand ihow iis iit iprevented iwhile ion iisoniazid? o Isoniazid iis iprescribed iwith ivitamin iB6 ito iprevent ithe iperipheral ineuropathy icommonly iexperienced ias ia iside-effect. • Varenilcine i(Chantix) iis ia ipartial iagonist ior iantagonist iat ithe inicotinic iacetylcholine ireceptors. iThis imeans iit istops inicotine ifrom ibinding ito ithe inicotine ireceptors, iand ithis causes iless idopamine ito ibe ireleased. iDopamine iis iassociated iwith ipleasure. iTherefore, ipatients ifeel iless ireward ifor ismoking. iBased ion ithe iside-effects ifor ieach iof ithese itreatments, ican iyou ishare iexamples iof ipatients ifor iwhich iyou iwould inot iwant ito iprescribe ieach iof ithese itreatments? o Chantix ihas iwarnings iabout iits ineuropsychiatric ieffects iso iyou iwould iwant ito iavoid iits iused iin ipatients iwith ipsychiatric iconditions. • Why iwould ia ilong iacting ibeta i2-adrenergic iagonist i(LABA) iand ian iinhaled icorticosteroid i(ICS) ibe iprescribed? iWhat iare isome iexamples iof ia iLABA/ICS? o When iused iin icombination iwith iLABA, iICS ihas iimproved icompliance iand icontrol iasthma ieffectively iat ilower idoses iof icorticosteroids o You ishould ibe ifamiliar iwith ithe icombination iproducts. iExamples iare ilisted iin iyour ibook: iTable i30-7 iin iTextbook. iP. i928. • What iis ithe imechanism iof iaction ifor iTheophylline? iWhy iis iit itypically iprescribed? iWhat isubstance ifound iin isome ifoods iand idrinks ican iinteract itheophylline?